PMC Group and The Chakrabarti Foundation Make Donation to Ramakrishna Mission Saradapitha Belur Math of West Bengal
14.3.2023 12:45:00 EET | Business Wire | Press release
Paritosh M. Chakrabarti, business owner, author and philanthropist, today announced PMC Group and The Chakrabarti Foundation have made a sizeable donation of land and property to the Ramakrishna Mission Saradapitha Belur Math of West Bengal.
“Contributing to the Ramakrishna Mission Saradapitha is an honor. The Mission enshrines the teachings of India’s greatest spiritual leader and unifier of humanity, Swami Vivekananda,” explained Paritosh Chakrabarti. “This gift is a way for me to further those ideals. I am appreciative to Belur Math for accepting the donation. These gifts are also part of the ‘soul’ of PMC Group that I describe in my upcoming book, The Makings of PMC Group – A Corporation with a Soul."
The donation includes the notable Bose House which has been witness to many historical events and carries memories of great patriots and revolutionaries, the surrounding land, and a significant financial gift. The financial gift will provide for 1.) construction and development of two museum rooms, each housing panel exhibition-cum-photo galleries, manuscripts, rare and valuable collections and potentially, a multimedia presentation depicting the lives, activities, and legacies of Swami Vivekananda and Netaji Subhas Chandra Bose, 2.) production of cultural and educational activities to promote inter-cultural and inter-religious harmony and, 3.) installation of a commemorative plaque stating: “This historic Bose House Property has been donated by Paritosh M. Chakrabarti and Srimati Chakrabarti to Ramakrishna Mission Saradapitha, Belur Math for the Construction and Development of a Cultural and Educational Center to Promote the legacy of Swamiji and Netaji”.
The chairman of Rishra Municipality, Vijay Sagar Mishra said, “It’s a matter of great joy and honor for all of us to watch the handing over ceremony of Rishra Bose House to Ramakrishna Mission Saradapitha Belur Math. Converting it to a museum will bring the common people closer to the works and activities of the great patriot Netaji Subhas Chandra Bose and Swami Vivekananda. The present generation must be made aware of the glorious history so that they can take lessons from it and go ahead in serving the motherland.”
ABOUT PMC
PMC Group, owned by Paritosh M. Chakrabarti and his family, is a US based growth oriented, diversified, global chemicals and pharmaceuticals company dedicated to innovative solutions to every need in a broad range of end markets including, plastics, consumer products, electronics, coatings, packaging, mining, personal care, food, automotive and pharmaceuticals. The Company was built on a sustainable model of growth through innovation while promoting social good. PMC operates from a global manufacturing, innovation, and marketing platform with facilities in the Americas, Europe, and Asia. More information about PMC Group and its activities around the world can be found at www.pmc-group.com.
ABOUT THE CHAKRABARTI FOUNDATION
The Chakrabarti Foundation is a non-profit organization dedicated to promoting education around the world and believes excellence in education is a primary requirement for enduring civilization. To learn more please visit https://pmc-group.com/chakrabarti-foundation.
ABOUT RAMAKRISHNA MISSION SARADAPITHA BELUR MATH
Ramakrishna Mission Saradapitha Belur Math is a well-known and reputed philanthropic organization serving the society of India and abroad irrespective of caste, color, creed, religion, nationality, gender, regional bias, etc., through its vast network of nearly more than 250 branch-centers in the fields of education, culture, religion, health, relief and rehabilitation, rural and tribal development, publications, teachings and preaching and a large number of allied areas all of which are for the all-around development of the individual and the society as a whole. More can be found at https://belurmath.org/ramakrishna-mission-saradapitha-belur.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005278/en/
Contact information
Patti Griggs 856-533-1870
pgriggs@pmc-group.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom